Hebei Changshan Biochem Pharma Total Liabilities
Hebei Changshan Biochem Pharma total liabilities. Based on the latest financial reports, Hebei Changshan Biochem Pharma (300255) has total liabilities worth CN¥3.18 Billion CNY (≈ $465.20 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Hebei Changshan Biochem Pharma liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hebei Changshan Biochem Pharma (2008–2024)
Total liabilities of Hebei Changshan Biochem Pharma from 2008 to 2024. This chart illustrates how Hebei Changshan Biochem Pharma's total liabilities have evolved over time, based on quarterly financial data. Explore 300255 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Hebei Changshan Biochem Pharma Competitors by Total Liabilities
The table below lists competitors of Hebei Changshan Biochem Pharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xiamen Xiangyu Co Ltd
SHG:600057
|
China | CN¥97.67 Billion |
|
PT Trimegah Bangun Persada Tbk
JK:NCKL
|
Indonesia | Rp15.20 Trillion |
|
Dana Inc
NYSE:DAN
|
USA | $6.89 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr1.63 Billion |
|
CN LGY.PWR.GR.UNSP.ADR/10
F:6WX0
|
Germany | €176.73 Billion |
|
Koninklijke BAM Groep NV
AS:BAMNB
|
Netherlands | €2.96 Billion |
|
Privia Health Group Inc
NASDAQ:PRVA
|
USA | $650.51 Billion |
|
Livzon Pharmaceutical Group Inc
SHE:000513
|
China | CN¥8.61 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Hebei Changshan Biochem Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Hebei Changshan Biochem Pharma balance sheet assets.
Liquidity & Leverage Metrics
Hebei Changshan Biochem Pharma Total Liabilities Ratios Explained
Hebei Changshan Biochem Pharma total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hebei Changshan Biochem Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hebei Changshan Biochem Pharma (2008–2024)
The table below shows the annual total liabilities of Hebei Changshan Biochem Pharma from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.99 Billion ≈ $437.10 Million |
+6.80% |
| 2023-12-31 | CN¥2.80 Billion ≈ $409.25 Million |
-6.20% |
| 2022-12-31 | CN¥2.98 Billion ≈ $436.33 Million |
+40.80% |
| 2021-12-31 | CN¥2.12 Billion ≈ $309.89 Million |
+23.17% |
| 2020-12-31 | CN¥1.72 Billion ≈ $251.59 Million |
+40.89% |
| 2019-12-31 | CN¥1.22 Billion ≈ $178.57 Million |
-7.68% |
| 2018-12-31 | CN¥1.32 Billion ≈ $193.42 Million |
+20.75% |
| 2017-12-31 | CN¥1.09 Billion ≈ $160.18 Million |
+29.92% |
| 2016-12-31 | CN¥842.59 Million ≈ $123.30 Million |
+11.30% |
| 2015-12-31 | CN¥757.07 Million ≈ $110.78 Million |
+22.53% |
| 2014-12-31 | CN¥617.87 Million ≈ $90.41 Million |
+71.74% |
| 2013-12-31 | CN¥359.78 Million ≈ $52.65 Million |
+22.89% |
| 2012-12-31 | CN¥292.77 Million ≈ $42.84 Million |
+47.29% |
| 2011-12-31 | CN¥198.78 Million ≈ $29.09 Million |
-5.91% |
| 2010-12-31 | CN¥211.25 Million ≈ $30.91 Million |
+97.15% |
| 2009-12-31 | CN¥107.15 Million ≈ $15.68 Million |
+3.87% |
| 2008-12-31 | CN¥103.16 Million ≈ $15.10 Million |
-- |
About Hebei Changshan Biochem Pharma
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. The company offers crude heparin sodium, heparin sodium API, heparin sodium injections, low molecular weight heparin calcium i… Read more